Signals from dying hepatocytes trigger growth of liver progenitors

被引:133
作者
Jung, Youngmi
Witek, Rafal P.
Syn, Wing-Kin
Choi, Steve S.
Omenetti, Alessia
Premont, Richard
Guy, Cynthia D. [2 ]
Diehl, Anna Mae [1 ]
机构
[1] Duke Univ, Div Gastroenterol, Dept Med, Durham, NC 27710 USA
[2] Duke Univ, Dept Pathol, Durham, NC 27710 USA
关键词
HEPATIC OVAL CELLS; IKK-BETA; HEDGEHOG; ACTIVATION; PREVENTION; APOPTOSIS; FIBROSIS;
D O I
10.1136/gut.2009.204354
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Objective The death rate of mature hepatocytes is chronically increased in various liver diseases, triggering responses that prevent liver atrophy, but often cause fibrosis. Mice with targeted disruption of inhibitor kappa B kinase (Ikk) in hepatocytes (Delta HEP mice) provide a model to investigate this process because inhibiting Ikk-nuclear factor-kappa B (NF-kappa B) signalling in hepatocytes increases their apoptosis. Methods Cell proliferation, apoptosis, progenitors, fibrosis and production of Hedgehog (Hh) ligands (progenitor and myofibroblast growth factors) were compared in Delta HEP and control mice before and after feeding methionine choline-deficient ethionine-supplemented (MCDE) diets. Ikk beta was deleted from primary hepatocytes to determine the effects on Hh ligand production; Hh signalling was inhibited directly in progenitors to determine the effects on viability. Liver sections from patients were examined to assess relationships between hepatocyte production of Hh ligands, accumulation of myofibroblastic cells and liver fibrosis. Results Disrupting the Ikk-NF-kappa B pathway in hepatocytes inhibited their proliferation but induced their production of Hh ligands. The latter provided viability signals for progenitors and myofibroblasts, enhancing accumulation of these cell types and causing fibrogenesis. Findings in the mouse models were recapitulated in diseased human livers. Conclusion Dying mature hepatocytes produce Hh ligands which promote the compensatory outgrowth of progenitors and myofibroblasts. These results help to explain why diseases that chronically increase hepatocyte death promote cirrhosis.
引用
收藏
页码:655 / 665
页数:11
相关论文
共 26 条
[1]   Pathology of nonalcoholic steatohepatitis [J].
Brunt, EM .
HEPATOLOGY RESEARCH, 2005, 33 (02) :68-71
[2]   Kupffer cell engulfment of apoptotic bodies stimulates death ligand and cytokine expression [J].
Canbay, A ;
Feldstein, AE ;
Higuchi, H ;
Werneburg, N ;
Grambihler, A ;
Bronk, SF ;
Gores, GJ .
HEPATOLOGY, 2003, 38 (05) :1188-1198
[3]   Hedgehog pathway activation and epithelial-to-mesenchymal transitions during myofibroblastic transformation of rat hepatic cells in culture and cirrhosis [J].
Choi, Steve S. ;
Omenetti, Alessia ;
Witek, Rafal P. ;
Moylan, Cynthia A. ;
Syn, Wing-Kin ;
Jung, Youngmi ;
Yang, Liu ;
Sudan, Debra L. ;
Sicklick, Jason K. ;
Michelotti, Gregory A. ;
Rojkind, Marcos ;
Diehl, Anna Mae .
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY, 2009, 297 (06) :G1093-G1106
[4]   A dominant negative form of IKK2 prevents suppression of apoptosis by the peroxisome proliferator nafenopin [J].
Cosulich, SC ;
James, NH ;
Needham, MRC ;
Newham, PP ;
Bundell, KR ;
Roberts, RA .
CARCINOGENESIS, 2000, 21 (09) :1757-1760
[5]   Neural trans-differentiation potential of hepatic oval cells in the neonatal mouse brain [J].
Deng, H ;
Steindler, DA ;
Laywell, ED ;
Petersen, BE .
EXPERIMENTAL NEUROLOGY, 2003, 182 (02) :373-382
[6]   Cytokeratin-18 Fragment Levels as Noninvasive Biomarkers for Nonalcoholic Steatohepatitis: A Multicenter Validation Study [J].
Feldstein, Ariel E. ;
Wieckowska, Anna ;
Lopez, A. Rocio ;
Liu, Yao-Chang ;
Zein, Nizar N. ;
McCullough, Arthur J. .
HEPATOLOGY, 2009, 50 (04) :1072-1078
[7]  
Hacker H., Sci. Signal, DOI [DOI 10.1126/STKE.3572006RE13, 10.1126/stke.3572006re13]
[8]   Hepatic fibrogenesis: From within and outwith [J].
Henderson, Neil C. ;
Forbes, Stuart J. .
TOXICOLOGY, 2008, 254 (03) :130-135
[9]  
HIXSON DC, 1985, CANCER RES, V45, P3750
[10]   Cholesterol modification of Hedgehog family proteins [J].
Jeong, J ;
McMahon, AP .
JOURNAL OF CLINICAL INVESTIGATION, 2002, 110 (05) :591-596